10-Q quarterly report · filed Nov 5, 2026

REGENXBIO Inc. (RGNX) Q3 2026 10-Q Quarterly Report

Short answer

REGENXBIO Inc. (RGNX) filed its Q3 2026 10-Q quarterly report on Nov 5, 2026 for the quarter ended Sep 30, 2026. Quarterly revenue was $9M (down 69.2% year over year) with net income of −$41M.

Q3 2026 key financials · XBRL

Revenue
$9M
−69.2% YoY · −91.5% QoQ
Net income
−$41M
+34.2% YoY · −279.4% QoQ
Operating margin
-387.8%
EPS (diluted)
−$0.62
+48.3% YoY · −240.9% QoQ

Source: XBRL data from the REGENXBIO Inc. (RGNX) Q3 2026 10-Q on SEC EDGAR. USD.

REGENXBIO Inc. Q3 2026 10-Q analysis

AI summary of MD&A and risk factor updates

Management Discussion & Analysis

  • Revenue $9.2M, down $20.6M YoY from $29.7M, driven by lower Zolgensma royalties
  • Operating loss $35.5M, versus $52.4M YoY; operating margin -387.8% vs -176.3%
  • Best performer: Itvisma royalties $2.8M; worst: Zolgensma royalties $2.4M, down $21.2M YoY
  • Cash, equivalents and marketable securities $251.0M; operating cash outflow $99.8M versus $71.7M YoY
  • $107.8M equity offering and $18.9M ATM proceeds; liquidity expected into late fourth quarter 2027, with substantial going-concern doubt

Risk Factors

  • No material changes from 2025 Form 10-K risk factors
  • Carried-forward risks remain the company’s material disclosed risks

Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K

Other REGENXBIO Inc. quarterly reports

Ask about this quarter

Compare quarters, check guidance or see what insiders and funds did around the report.